Trial Profile
An Open-Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Rhythm
- 23 Mar 2021 Results from NCT02507492, NCT02896192 and NCT03287960 evaluating onset of adverse events in patients with POMC/PCSK1 or LEPR deficiency obesity treated with setmelanotide, presented at the 103rd Annual Meeting of the Endocrine Society
- 09 Mar 2021 According to a Rhythm Pharmaceuticals media release, data from this study will be presented by Karine Clement at the 103rd Annual Meeting and Expo of the Endocrine Society (ENDO 2021).
- 22 Oct 2020 This trial has been completed in Germany (Global End Date: 16 Jul 2020), according to European Clinical Trials Database record.